文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

血管加压素与甲泼尼龙对院内心搏骤停后血流动力学的影响——VAM-IHCA试验的事后分析

Vasopressin and methylprednisolone and hemodynamics after in-hospital cardiac arrest - A post hoc analysis of the VAM-IHCA trial.
PubMed 文献 · Resuscitation · 2023-08-03
一句话结论VAM-IHCA事后分析显示,心搏骤停期间使用血管加压素与甲泼尼龙未改变ROSC后24小时内的平均动脉压、升压药用量或动脉血气。

本研究为VAM-IHCA试验的事后分析,纳入该试验中186例实现ROSC的院内心搏骤停患者,其中100例接受血管加压素与甲泼尼龙联合治疗,86例接受安慰剂。比较ROSC后24小时内糖皮质激素使用、平均动脉压、心率、血气、升压药与正性肌力药治疗及镇静情况,总升压药剂量按去甲肾上腺素等效剂量计算。结果显示两组平均累积去甲肾上腺素等效剂量无显著差异(血管加压素与甲泼尼龙组603 μg/kg [95%CI 227; 979] vs 安慰剂组651 μg/kg [95%CI 296; 1007],平均差-48 μg/kg [95%CI -140; 42.9],p=0.30),平均动脉压、乳酸水平、动脉血气值及生命体征均无差异。

要点

  • ROSC后24小时内平均累积去甲肾上腺素等效剂量:血管加压素与甲泼尼龙组603 μg/kg(95%CI 227; 979)vs 安慰剂组651 μg/kg(95%CI 296; 1007),平均差-48 μg/kg(95%CI -140; 42.9),p=0.30
  • ROSC后24小时内接受糖皮质激素的患者比例:安慰剂组22/86(26%)vs 甲泼尼龙组14/100(14%),两组累积氢化可的松等效剂量无差异
  • 两组平均动脉血压、乳酸水平、动脉血气值及生命体征均无差异
  • 心搏骤停期间使用血管加压素与甲泼尼龙未改善ROSC后24小时内的血流动力学指标

适用人群与场景

  • VAM-IHCA试验中实现ROSC的院内心搏骤停患者,共186例(血管加压素与甲泼尼龙组100例,安慰剂组86例)

研究设计与关键结果

  • 研究类型:VAM-IHCA试验的事后分析,纳入该试验中186例实现ROSC的院内心搏骤停患者,其中100例接受血管加压素与甲泼尼龙联合治疗,86例接受安慰剂
  • 主要终点:ROSC后24小时内平均累积去甲肾上腺素等效剂量,血管加压素与甲泼尼龙组603 μg/kg(95%CI 227; 979)vs 安慰剂组651 μg/kg(95%CI 296; 1007),平均差-48 μg/kg(95%CI -140; 42.9),p=0.30
  • ROSC后24小时内接受糖皮质激素的患者:安慰剂组22/86(26%)vs 甲泼尼龙组14/100(14%),累积氢化可的松等效剂量无差异
  • 两组平均动脉血压、乳酸水平、动脉血气值及生命体征均无差异

证据类型、等级与局限

  • 证据类型:随机对照试验(VAM-IHCA)的事后分析
  • 局限:原文未报告局限性

对床旁实践的改变

  • 对于院内心搏骤停患者,心搏骤停期间使用血管加压素与甲泼尼龙并未改变ROSC后24小时内的平均动脉压、升压药用量或动脉血气,不支持以改善ROSC后早期血流动力学为目的使用该联合治疗

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) trial demonstrated a significant improvement in return of spontaneous circulation (ROSC) with no clear effect on long-term outcomes. The objective of the current manuscript was to evaluate the hemodynamic effects of intra-cardiac arrest vasopressin and methylprednisolone during the first 24 hours after ROSC.

METHODS: The VAM-IHCA trial randomized patients with in-hospital cardiac arrest to a combination of vasopressin and methylprednisolone or placebo during the cardiac arrest. This study is a post hoc analysis focused on the hemodynamic effects of the intervention after ROSC. Post-ROSC data on the administration of glucocorticoids, mean arterial blood pressure, heart rate, blood gases, vasopressor and inotropic therapy, and sedation were collected. Total vasopressor dose between the two groups was calculated based on noradrenaline-equivalent doses for adrenaline, phenylephrine, terlipressin, and vasopressin.

RESULTS: The present study included all 186 patients who achieved ROSC in the VAM IHCA-trial of which 100 patients received vasopressin and methylprednisolone and 86 received placebo. The number of patients receiving glucocorticoids during the first 24 hours was 22/86 (26%) in the placebo group and 14/100 (14%) in the methylprednisolone group with no difference in the cumulative hydrocortisone-equivalent dose. There was no significant difference between the groups in the mean cumulative noradrenaline-equivalent dose (vasopressin and methylprednisolone: 603 ug/kg [95CI% 227; 979] vs. placebo: 651 ug/kg [95CI% 296; 1007], mean difference -48 ug/kg [95CI% -140; 42.9], p = 0.30), mean arterial blood pressure, or lactate levels. There was no difference between groups in arterial blood gas values and vital signs.

CONCLUSION: Treatment with vasopressin and methylprednisolone during cardiac arrest caused no difference in mean arterial blood pressure, vasopressor use, or arterial blood gases within the first 24 hours after ROSC when compared to placebo.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Andersen LW, Holmberg MJ, Høybye M, et al. Vasopressin and methylprednisolone and hemodynamics after in-hospital cardiac arrest - A post hoc analysis of the VAM-IHCA trial. Resuscitation. 2023. PMID: 37543161. doi:10.1016/j.resuscitation.2023.109922

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。